latest update:
[TrialBase DB]

trial summary · NCT07557056

Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase 2 Study of Nemtabrutinib and Venetoclax as Frontline Treatment for Chronic Lymphocytic Leukemia (CLL)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Chronic Lymphocytic Leukemia, sponsored by Jennifer Woyach. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07557056phase PHASE2enrollment 25start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase II trial tests how well nemtabrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as CLL or SLL at abnormal levels. This may help keep cancer cells from growing and spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Giving nemtabrutinib in combination with venetoclax may kill more cancer cells in patients with CLL or SLL.

Source record: https://clinicaltrials.gov/study/NCT07557056

Facts

registry idNCT07557056
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionChronic Lymphocytic Leukemia
sponsorJennifer Woyach
sponsor classOTHER
enrollment25
start date2026-11-01
primary completion2027-12-31
completion2027-12-31
results postednot reported

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Computed Tomography
  • Nemtabrutinib
  • Questionnaire Administration
  • Venetoclax

Countries

  • United States

Intervention types: DRUG, OTHER, PROCEDURE

Work with this record